- Home
- LSBK vs HURA Comparison
LSBK vs HURA Comparison
Compare LSBK & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | LSBK | HURA |
|---|---|---|
| Founded | 1891 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.0M | 131.8M |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | LSBK | HURA |
|---|---|---|
| Price | $15.44 | $0.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 8.2K | ★ 392.8K |
| Earning Date | 01-26-2026 | 02-14-2026 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | ★ 105.28 | N/A |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $27,774,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.79 | ★ N/A |
| Revenue Growth | ★ 9.61 | N/A |
| 52 Week Low | $11.50 | $0.70 |
| 52 Week High | $16.95 | $5.27 |
Technical Indicators
Market Signals| Indicator | LSBK | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 63.15 | 32.60 |
| Support Level | $14.80 | $0.70 |
| Resistance Level | $15.48 | $0.81 |
| Average True Range (ATR) | 0.24 | 0.06 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 71.95 | 58.33 |
Price Performance
Historical ComparisonAbout LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.